TERN-701  Chronic Myeloid Leukemia   CML

"

SITE 

CLINICAL TRIALS

CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia

                        All clinical trials with Terms-701

ARTICLES 

TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML
December 12, 2025, OncLive

Terns drug shows potential to challenge Novartis’ blockbuster leukemia treatment
December 8, 2025, BioPharmaDive
 
Terns Pharmaceuticals’ Allosteric Inhibitor Shows “Best-in-Class” Potential in Phase I CML Study
December 4, 2024, InsidePercisionMedicine
 
TERN-701 Decreases BCR-ABL Levels, Generates Molecular Responses in R/R CML
December 4, 2024, OncLive

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
December 03, 2024 , GlobeNewswire

TERN-701 Shows Promising Early Results in Heavily Pre-Treated CML
December 3, 2024,  Targeted Oncology
​
​

                                        See also Mutation T315I